Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05241093 | A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 18 | Tarapeutics Science Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06530511 | Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL | unknown | Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 4, 2025 |
| clinicaltrials |
| NCT03225417 | Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | unknown | Phase 1 / Phase 2 | 142 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT05272293 | Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05334693 | Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05914662 | Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM(ZBR) | unknown | Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06149169 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma | unknown | Phase 2 | 10 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04914741 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)(COALITION) | unknown | Phase 1 / Phase 2 | 80 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT05749549 | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | unknown | Phase 1 / Phase 2 | 191 | Shanghai Blueray Biopharma Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06468267 | RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. | unknown | Phase 2 | 50 | Xianmin Song, MDOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06427330 | Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia | unknown | Phase 2 | 21 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT05842785 | TSN222 in Subjects With Advanced Solid Tumors or Lymphomas | unknown | Phase 1 / Phase 2 | 162 | Tyligand Bioscience (Shanghai) LimitedINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06503094 | CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors | unknown | Phase 1 / Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06492629 | Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma | unknown | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02628405 | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT04778579 | Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy(CART19-BE-02) | unknown | Phase 2 | 50 | Sara V. LatorreOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03293173 | Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis(Bio-CHIC) | unknown | Phase 2 | 120 | Nordic Lymphoma GroupNETWORK | 4 | Jun 21, 2024 | clinicaltrials |
| NCT03942224 | Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma(DeRIVE) | unknown | Phase 2 | 49 | Emory UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05422027 | Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 42 | Xia ZhongjunOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT05422066 | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 50 | Li ZhimingOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT02061800 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | unknown | Phase 1 / Phase 2 | 14 | Diane GeorgeOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05493800 | Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT(Capella) | unknown | Phase 2 | 60 | MitoImmune TherapeuticsINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT06433362 | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma | unknown | Phase 2 | 115 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT01305499 | A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 52 | Hetty CarrawayOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT03275493 | CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia | unknown | Phase 1 / Phase 2 | 40 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05189197 | A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06415708 | Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma | unknown | Phase 2 | 134 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03188172 | MUK Nine b: OPTIMUM Treatment Protocol(MUKnineb) | unknown | Phase 2 | 95 | University of LeedsOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT05241106 | A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 2 | 15 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT05396118 | Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients | unknown | Phase 2 | 15 | Rigshospitalet, DenmarkOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06173999 | A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT06412068 | A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 0 | May 14, 2024 | clinicaltrials |
| NCT03337919 | ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma(ANIMATE) | unknown | Phase 2 | 78 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT04655118 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | unknown | Phase 2 | 121 | Telios Pharma, Inc.INDUSTRY | 13 | May 10, 2024 | clinicaltrials |
| NCT01428973 | Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens | unknown | Phase 2 | 200 | University of LiegeOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06406556 | Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL(ENKTL) | unknown | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT03292263 | ASCT With Nivolumab in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT04499339 | A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | Wuerzburg University HospitalOTHER | 3 | Apr 25, 2024 | clinicaltrials |
| NCT04745234 | Mogamulizumab Q4week Dosing in Participants With R/R CTCL | unknown | Phase 2 | 34 | Kyowa Kirin, Inc.INDUSTRY | 5 | Apr 25, 2024 | clinicaltrials |
| NCT06189833 | Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS(TAURUS) | unknown | Phase 2 | 200 | Stichting European Myeloma NetworkNETWORK | 5 | Apr 23, 2024 | clinicaltrials |
| NCT06078306 | CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03412409 | RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT | unknown | Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06279494 | Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors | unknown | Phase 1 / Phase 2 | 6 | Peking University People's HospitalOTHER | 0 | Mar 21, 2024 | clinicaltrials |
| NCT06324266 | Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation | unknown | Phase 2 / Phase 3 | 80 | Jinling Hospital, ChinaOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT03975907 | Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) | unknown | Phase 1 / Phase 2 | 121 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05387616 | A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden(Alternative-C) | unknown | Phase 2 | 98 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05066607 | Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy(IsAMYP) | unknown | Phase 2 | 46 | Intergroupe Francophone du MyelomeNETWORK | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05370547 | Chidamide Bridging for CAR-T Therapy | unknown | Phase 1 / Phase 2 | 120 | Chinese PLA General HospitalOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06242249 | Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shahid Beheshti University of Medical SciencesOTHER | 1 | Mar 6, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Apr 10, 2025source: clinicaltrials